HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stefan Stevanovic Selected Research

HLA-A*02:01 antigen

5/2009Identification of an immunogenic HLA-A*0201-binding T-cell epitope of the transcription factor PAX2.
10/2005Melanoma patients respond to a new HLA-A*01-presented antigenic ligand derived from a multi-epitope region of melanoma antigen TRP-2.
6/2004Identification of C-met oncogene as a broadly expressed tumor-associated antigen recognized by cytotoxic T-lymphocytes.
2/2004Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.
12/2003Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
9/2003Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8.
12/2002Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients.
5/2002Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stefan Stevanovic Research Topics

Disease

50Neoplasms (Cancer)
01/2020 - 02/2002
10Renal Cell Carcinoma (Grawitz Tumor)
11/2013 - 06/2004
10Melanoma (Melanoma, Malignant)
08/2007 - 02/2002
8Infections
10/2020 - 05/2002
7Testicular Neoplasms (Testicular Cancer)
09/2011 - 12/2003
5Multiple Sclerosis
11/2020 - 05/2004
4Glioma (Gliomas)
01/2021 - 01/2007
4Virus Diseases (Viral Diseases)
10/2020 - 01/2007
4Glioblastoma (Glioblastoma Multiforme)
03/2019 - 09/2005
4Inflammation (Inflammations)
01/2016 - 03/2006
4Prostatic Neoplasms (Prostate Cancer)
07/2014 - 12/2002
3Ovarian Neoplasms (Ovarian Cancer)
01/2019 - 08/2007
3Colorectal Neoplasms (Colorectal Cancer)
01/2019 - 05/2009
3Leukemia
07/2017 - 03/2004
3Breast Neoplasms (Breast Cancer)
09/2011 - 02/2003
3Carcinoma (Carcinomatosis)
06/2009 - 09/2003
2Hematologic Neoplasms (Hematological Malignancy)
07/2017 - 12/2006
2B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2015 - 02/2004
2Urinary Bladder Neoplasms (Bladder Cancer)
01/2015 - 07/2014
2Autoimmune Diseases (Autoimmune Disease)
06/2013 - 08/2003
2Lymphoma (Lymphomas)
05/2009 - 11/2005
2Synovial Sarcoma (Synovioma)
08/2007 - 06/2004
2Plasma Cell Leukemia
06/2004 - 02/2004
2Graft vs Host Disease (Graft-Versus-Host Disease)
03/2004 - 06/2002
1Neuroblastoma
11/2021
1Carcinogenesis
01/2020
1Sepsis (Septicemia)
01/2016
1Acute Monocytic Leukemia (Acute Monoblastic Leukemia)
07/2014
1Burkitt Lymphoma (Burkitt's Lymphoma)
07/2014
1Wounds and Injuries (Trauma)
01/2014
1Lymphoproliferative Disorders (Lymphoproliferative Disorder)
01/2013
1Connective Tissue Diseases (Connective Tissue Disease)
02/2012
1Biliary Liver Cirrhosis (Primary Biliary Cirrhosis)
02/2012
1Hepatitis
02/2012
1Necrosis
01/2012
1Central Nervous System Lupus Vasculitis
02/2011
1Epilepsy (Aura)
02/2011
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
02/2011
1Acute Erythroblastic Leukemia (Erythroleukemia)
08/2010
1Central Nervous System Diseases (CNS Diseases)
09/2009

Drug/Important Bio-Agent (IBA)

40Peptides (Polypeptides)IBA
11/2021 - 02/2002
36AntigensIBA
01/2019 - 03/2002
24EpitopesIBA
07/2017 - 02/2002
23Proteins (Proteins, Gene)FDA Link
11/2021 - 05/2002
10VaccinesIBA
01/2021 - 07/2008
9LigandsIBA
01/2019 - 09/2005
8T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA
08/2009 - 02/2002
8HLA-A*02:01 antigenIBA
05/2009 - 05/2002
6Neoplasm Antigens (Tumor Antigens)IBA
01/2019 - 03/2002
6HLA-A Antigens (HLA-A)IBA
04/2012 - 12/2003
5Protein Subunit VaccinesIBA
01/2021 - 12/2003
5AntibodiesIBA
09/2013 - 12/2008
4HLA-DR Antigens (HLA-DR)IBA
07/2008 - 07/2004
4Cancer VaccinesIBA
06/2007 - 02/2004
3AutoantigensIBA
01/2019 - 05/2004
3HemocyaninsIBA
06/2015 - 07/2014
3HLA Antigens (Human Leukocyte Antigens)IBA
06/2011 - 01/2007
3Proteasome Endopeptidase Complex (Proteasome)IBA
05/2009 - 02/2002
3Messenger RNA (mRNA)IBA
01/2007 - 09/2003
2HLA-DR15 antigenIBA
11/2020 - 06/2013
2InterferonsIBA
03/2019 - 08/2009
2CytokinesIBA
01/2015 - 05/2009
2Interleukin-2 (IL2)IBA
11/2013 - 03/2002
2Cyclin D1IBA
11/2013 - 12/2004
2Myelin Basic ProteinIBA
09/2009 - 05/2004
2Histocompatibility Antigens Class IIIBA
09/2009 - 03/2006
2Transcription Factors (Transcription Factor)IBA
05/2009 - 12/2006
2Peptide Hydrolases (Proteases)FDA Link
08/2008 - 08/2003
2Monophenol Monooxygenase (Tyrosinase)IBA
05/2002 - 03/2002
1HLA-A*24:02 antigenIBA
11/2021
1Codon (Codons)IBA
01/2021
1ChemokinesIBA
03/2019
1Janus KinasesIBA
03/2019
1Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019
1Cathepsin GIBA
03/2016
1Histocompatibility Antigens Class IIBA
03/2016
1Toll-Like Receptor 2IBA
01/2016
1Immune Checkpoint InhibitorsIBA
01/2015
1Rapana venosa hemocyaninIBA
01/2015
1Pharmaceutical PreparationsIBA
01/2014
1Laminin (Merosin)IBA
01/2014
1Imiquimod (Aldara)FDA LinkGeneric
01/2014
1CyclinsIBA
11/2013
1Complementary DNA (cDNA)IBA
09/2013
1Immunoglobulin G (IgG)IBA
09/2013
1Peptide LibraryIBA
06/2013
1Epstein-Barr Virus Nuclear AntigensIBA
01/2013
1IMA950IBA
04/2012
1Annexin A1IBA
01/2012
1Surface Antigens (Surface Antigen)IBA
06/2011
1TubulinIBA
02/2011
1HLA-A2 Antigen (HLA A2 Antigen)IBA
08/2010
1Capsid Proteins (Capsid Protein)IBA
08/2009

Therapy/Procedure

23Immunotherapy
01/2020 - 02/2002
4Therapeutics
03/2019 - 03/2002
4Stem Cell Transplantation
01/2013 - 06/2002
2Drug Therapy (Chemotherapy)
03/2004 - 06/2002
1Aftercare (After-Treatment)
01/2015
1Transplantation
01/2013
1Hematopoietic Stem Cell Transplantation
01/2013